Navigation Links
Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
Date:6/15/2010

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of the drugs in Isis' pipeline.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009 and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.  

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of ... than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More ... Headquartered in Dallas, TX , ISN has additional offices ...
(Date:7/30/2015)... ST. LOUIS, July 30, 2015 ... period in 2014) , Reported sales were $697 ... of 2014.  Sales grew organically by 8%, and changes ... Recent acquisitions increased sales by 1%. , By ... 8% in Applied and 11% in SAFC Commercial. ...
(Date:7/30/2015)... ... ... As part of its 2015 growth plan and as a follow up to the recently ... Whitehouse Laboratories is pleased to announce that it has begun construction on a new Microbiological ... will be strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific ...
(Date:7/29/2015)... Sanofi, a global and ... quarter of 2015. CEO Olivier Brandicourt ... in different businesses. Watch video interview ... Topics covered in the interview include:  ... Performance drivers - Diabetes ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... , , , ... FOLD ) will announce second quarter 2009 financial results after the ... announcement will be followed by a live conference call and webcast ... Interested participants and investors may access the conference call at ...
... , ... Change at ... constant on a constant, ... 2009 basis rates H1 2009 basis rates, ...
... , ... in Cardiac Core Lab Industry , ... Rochester, NY (PRWEB) July 29, 2009 -- iCardiac Technologies, Inc., a leader in advanced ... of 45 million cardiac cycles for agency facing studies in a single month utilizing the ...
Cached Biology Technology:Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date 2Sanofi-aventis Announces Second Quarter 2009 Results 2Sanofi-aventis Announces Second Quarter 2009 Results 3Sanofi-aventis Announces Second Quarter 2009 Results 4Sanofi-aventis Announces Second Quarter 2009 Results 5Sanofi-aventis Announces Second Quarter 2009 Results 6Sanofi-aventis Announces Second Quarter 2009 Results 7Sanofi-aventis Announces Second Quarter 2009 Results 8Sanofi-aventis Announces Second Quarter 2009 Results 9Sanofi-aventis Announces Second Quarter 2009 Results 10Sanofi-aventis Announces Second Quarter 2009 Results 11Sanofi-aventis Announces Second Quarter 2009 Results 12Sanofi-aventis Announces Second Quarter 2009 Results 13Sanofi-aventis Announces Second Quarter 2009 Results 14Sanofi-aventis Announces Second Quarter 2009 Results 15Sanofi-aventis Announces Second Quarter 2009 Results 16Sanofi-aventis Announces Second Quarter 2009 Results 17Sanofi-aventis Announces Second Quarter 2009 Results 18Sanofi-aventis Announces Second Quarter 2009 Results 19Sanofi-aventis Announces Second Quarter 2009 Results 20Sanofi-aventis Announces Second Quarter 2009 Results 21Sanofi-aventis Announces Second Quarter 2009 Results 22Sanofi-aventis Announces Second Quarter 2009 Results 23Sanofi-aventis Announces Second Quarter 2009 Results 24Sanofi-aventis Announces Second Quarter 2009 Results 25Sanofi-aventis Announces Second Quarter 2009 Results 26Sanofi-aventis Announces Second Quarter 2009 Results 27iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies 2
(Date:7/23/2015)... BEDFORD, Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... services, today reported financial results for its second quarter ended ... quarter of 2015 was $4.5 million, a decrease of 33% ...  Net income in the second quarter of 2015 was $0.3 ... million, or $0.04 per diluted share, in the same period ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... Apricots are important to Turkey, the country where more ... the world. Looking to unlock the mystery of apricots, ... genetic relationship between apricot varieties. New research from a ... genetic link between Turkish and Hungarian apricot cultivars, yielding ...
... a recent issue of HortTechnology , Purdue University researchers ... study of the effects of a technique called "bulb dipping" ... applied as sprays or media drenches, bulb crops can be ... were designed to determine if dipping Easter lily bulbs in ...
... the XXI century. Recent data point to more than a ... 300 million are clinically obese. What is more, the rates ... 155 million children and adolescents being overweight, of which 40 ... what point corporal morphology was influenced by genetics, on the ...
Cached Biology News:Genetic relationship between Hungarian and Turkish apricots confirmed 2Bulb dipping controls Easter lily growth 2The amount of adipose tissue should be taken into account in the fight against obesity 2The amount of adipose tissue should be taken into account in the fight against obesity 3
... 96 wells. ELISA.Specific for total MMP-3: Recognizes ... cross-reactivity with MMP-1, -2, -9. Range: 3.75-120 ... cell culture supernatant, serum, plasma and tissue ... C. Category: Drug Screening & Cellular ...
... P Set from different human fetal ... organs maybe available upon request. ... from the whole set, and pay ... All Dr. P Set products ...
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Self Closing Forceps...
Biology Products: